| NCT04167514 |
Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone |
https://ClinicalTrials.gov/show/NCT04167514 |
Recruiting |
CSL Behring |
2023-11-30 |
| NCT03774082 |
Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT03774082 |
Recruiting |
Novartis |
2023-12-22 |
| NCT03755414 |
Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation |
https://ClinicalTrials.gov/show/NCT03755414 |
Recruiting |
Washington University School of Medicine |
2022-06-30 |
| NCT03640481 |
Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy |
https://ClinicalTrials.gov/show/NCT03640481 |
Active, not recruiting |
Kadmon Corporation, LLC |
2020-09-30 |
| NCT03395860 |
Low Dose ATG Plus Low Dose PTCy as GVHD Prophylaxis in Haplo-HSCT |
https://ClinicalTrials.gov/show/NCT03395860 |
Recruiting |
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine |
2020-05-20 |
| NCT03395340 |
Topical Ruxolitinib for Cutaneous Chronic Graft Versus Host Disease (cGVHD) |
https://ClinicalTrials.gov/show/NCT03395340 |
Recruiting |
National Institutes of Health Clinical Center (CC) |
2020-10-01 |
| NCT03371667 |
To Compare the Efficacy of the Addition of Methotrexate (MTX) to Current Standard Acute Graft-versus-host Disease (GVHD) First-line Treatment With Corticosteroids |
https://ClinicalTrials.gov/show/NCT03371667 |
Recruiting |
Assistance Publique - Hôpitaux de Paris |
2021-09-30 |
| NCT03367962 |
Detection of Graft Versus Host Disease With [18F]F-AraG |
https://ClinicalTrials.gov/show/NCT03367962 |
Recruiting |
CellSight Technologies, Inc. |
2019-12-31 |
| NCT03357159 |
Anti T-lymphocyte Immunoglobulin With Post Transplant Cyclophosphamide to Prevent GVHD Post Allogeneic Transplantation |
https://ClinicalTrials.gov/show/NCT03357159 |
Recruiting |
Sheba Medical Center |
2020-12-01 |
| NCT03340155 |
Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases |
https://ClinicalTrials.gov/show/NCT03340155 |
Recruiting |
Medical University of Graz |
2022-10-31 |
| NCT03327857 |
Neihulizumab (AbGn-168H) in Patients With Steroid-refractory Acute Graft-versus-host Disease |
https://ClinicalTrials.gov/show/NCT03327857 |
Recruiting |
AbGenomics International, Inc. |
2020-04-30 |
| NCT03320642 |
GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease |
https://ClinicalTrials.gov/show/NCT03320642 |
Recruiting |
Incyte Corporation |
2020-07-31 |
| NCT03315741 |
The Safety and Tolerability of Pirfenidone for BOS After HCT |
https://ClinicalTrials.gov/show/NCT03315741 |
Recruiting |
Stanford University |
2020-01-31 |
| NCT03298815 |
Study for the Treatment of Ocular Chronic Graft-Versus-Host Disease (GVHD) With Amniotic Fluid Eye Drops (AFED) |
https://ClinicalTrials.gov/show/NCT03298815 |
Recruiting |
University of Utah |
2024-11-30 |
| NCT03263767 |
Post Transplant Cyclophosphamide (PTCY) as Sole Graft Versus Host Disease (GVHD) Prophylaxis for Matched Allotransplant: CYRIC |
https://ClinicalTrials.gov/show/NCT03263767 |
Recruiting |
Nantes University Hospital |
2021-04-30 |
| NCT03229200 |
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. |
https://ClinicalTrials.gov/show/NCT03229200 |
Enrolling by invitation |
Pharmacyclics Switzerland GmbH |
2027-07-02 |
| NCT03225417 |
Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease. |
https://ClinicalTrials.gov/show/NCT03225417 |
Recruiting |
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla |
2022-04-16 |
| NCT03207958 |
Belimumab for Prevention of Chronic Graft-versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation |
https://ClinicalTrials.gov/show/NCT03207958 |
Recruiting |
Washington University School of Medicine |
2021-07-31 |
| NCT03204721 |
Prevention of GVHD in Patients Treated With Allogeneic SCT: Possible Role of Extracorporeal Photophoresis |
https://ClinicalTrials.gov/show/NCT03204721 |
Active, not recruiting |
Oslo University Hospital |
2021-12-31 |
| NCT03158896 |
Evaluation of Umbilical Cord-Derived Wharton’s Jelly Stem Cells for the Treatment of Acute Graft Versus Host Disease |
https://ClinicalTrials.gov/show/NCT03158896 |
Active, not recruiting |
University of Kansas Medical Center |
2020-08-31 |
| NCT03139604 |
GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease |
https://ClinicalTrials.gov/show/NCT03139604 |
Active, not recruiting |
Incyte Corporation |
2019-05-02 |
| NCT03128359 |
High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT03128359 |
Recruiting |
City of Hope Medical Center |
2021-01-31 |
| NCT03112603 |
A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3) |
https://ClinicalTrials.gov/show/NCT03112603 |
Active, not recruiting |
Incyte Corporation |
2020-05-27 |
| NCT03109353 |
Modification of Extracorporeal Photopheresis in Cutaneous T-cell Lymphoma or Chronic Graft-versus-host Disease |
https://ClinicalTrials.gov/show/NCT03109353 |
Active, not recruiting |
St. Olavs Hospital |
2020-09-30 |
| NCT03093805 |
Topical Vitamin D in Acute Graft Versus Host Disease of the Skin |
https://ClinicalTrials.gov/show/NCT03093805 |
Completed |
Children’s Hospital Medical Center, Cincinnati |
2019-03-04 |
| NCT03083574 |
Extracorporeal Photopheresis Using Theraflex ECPâ„¢ for Patients With Refractory Chronic Graft Versus Host Disease (cGVHD) |
https://ClinicalTrials.gov/show/NCT03083574 |
Recruiting |
Jules Bordet Institute |
2022-09-30 |
| NCT03057054 |
Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT03057054 |
Recruiting |
Children’s Oncology Group |
2023-08-01 |
| NCT03007238 |
Extracorporeal Photopheresis and Low Dose Aldesleukin in Treating Patients With Steroid Refractory Chronic Graft-Versus-Host Disease |
https://ClinicalTrials.gov/show/NCT03007238 |
Active, not recruiting |
City of Hope Medical Center |
2020-12-31 |
| NCT02997280 |
Ruxolitinib for Steroid-refractory GVHD |
https://ClinicalTrials.gov/show/NCT02997280 |
Completed |
St. Petersburg State Pavlov Medical University |
2018-12-31 |
| NCT02966301 |
Treatment of Chronic Graft Versus Host Disease With Arsenic Trioxide |
https://ClinicalTrials.gov/show/NCT02966301 |
Active, not recruiting |
Medsenic |
2020-06-30 |
| NCT02959944 |
Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Subjects With New Onset cGVHD |
https://ClinicalTrials.gov/show/NCT02959944 |
Active, not recruiting |
Pharmacyclics LLC. |
2020-07-31 |
| NCT02945176 |
Safety and Performance Study of the ARGOS-IO System in Patients Undergoing Boston Keratoprosthesis Implantation |
https://ClinicalTrials.gov/show/NCT02945176 |
Completed |
Implandata Ophthalmic Products GmbH |
2017-06-14 |
| NCT02942173 |
CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCT |
https://ClinicalTrials.gov/show/NCT02942173 |
Active, not recruiting |
Federal Research Institute of Pediatric Hematology, Oncology and Immunology |
2019-08-21 |
| NCT02923375 |
A Study of CYP-001 for the Treatment of Steroid-Resistant Acute Graft Versus Host Disease |
https://ClinicalTrials.gov/show/NCT02923375 |
Active, not recruiting |
Cynata Therapeutics Limited |
2018-08-28 |
| NCT02918188 |
Therapeutic Effects of Hydrogen on Steroid-refractory/or Steroid-dependent cGVHD |
https://ClinicalTrials.gov/show/NCT02918188 |
Recruiting |
Navy General Hospital, Beijing |
2026-01-31 |
| NCT02891395 |
Efficacy and Safety of Nilotinib in Patients With a Chronic Disease of the Graft Against the Host |
https://ClinicalTrials.gov/show/NCT02891395 |
Completed |
University Hospital, Lille |
2017-07-26 |
| NCT02876679 |
Cyclophosphamide Versus Anti-thymocyte Globulin for GVHD Prophylaxis After RIC Allo-SCT |
https://ClinicalTrials.gov/show/NCT02876679 |
Recruiting |
Assistance Publique - Hôpitaux de Paris |
2020-02-29 |
| NCT02867384 |
Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT02867384 |
Recruiting |
Dana-Farber Cancer Institute |
2022-02-28 |
| NCT02849886 |
T Lymphocytes (LT) Expressing iCASP9 and ΔCD19 in Allogeneic Haematopoietic Transplantation. |
https://ClinicalTrials.gov/show/NCT02849886 |
Recruiting |
Centre Hospitalier Universitaire de Besancon |
2020-12-31 |
| NCT02828878 |
Prevention of Acute Graft Versus Host Disease in Patients Undergoing Allogeneic ApoGraft Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT02828878 |
Recruiting |
Cellect Biotechnology |
2020-07-31 |
| NCT02824653 |
Allogenic Bone Marrow Mesenchymal Stem Cells Infusion in Patients With Steroid-refractory GVHD |
https://ClinicalTrials.gov/show/NCT02824653 |
Completed |
National Institute of Blood and Marrow Transplant (NIBMT), Pakistan |
2016-07-31 |
| NCT02805946 |
Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections |
https://ClinicalTrials.gov/show/NCT02805946 |
Completed |
Radboud University |
2019-07-26 |
| NCT02759731 |
Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT02759731 |
Recruiting |
National Institutes of Health Clinical Center (CC) |
2022-06-01 |
| NCT02749084 |
Multiple Donor Treg DLI for Severe Refractory Chronic GVHD |
https://ClinicalTrials.gov/show/NCT02749084 |
Recruiting |
Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi |
2020-03-31 |
| NCT02743351 |
Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT02743351 |
Recruiting |
Fate Therapeutics |
2020-04-30 |
| NCT02737306 |
Study of PRO 140 for Prophylaxis of Acute GVHD in Patients Undergoing RIC Allogenic Stem-Cell Transplantaton |
https://ClinicalTrials.gov/show/NCT02737306 |
Recruiting |
CytoDyn, Inc. |
2019-12-31 |
| NCT02707354 |
Early Detection of Mucosal Abnormalities in Graft-versus-host Disease |
https://ClinicalTrials.gov/show/NCT02707354 |
Completed |
Nantes University Hospital |
2018-08-20 |
| NCT02687646 |
Clinical Trial With MSC for Graft Versus Host Disease Treatment |
https://ClinicalTrials.gov/show/NCT02687646 |
Recruiting |
Andalusian Network for Design and Translation of Advanced Therapies |
2022-06-30 |
| NCT02683525 |
Sitagliptin for Prevention of Acute Graft Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT02683525 |
Active, not recruiting |
Indiana University |
2019-02-13 |
| NCT02669251 |
Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT02669251 |
Recruiting |
National Institutes of Health Clinical Center (CC) |
2020-09-30 |
| NCT02663622 |
Phase II Trial of CD24Fc for the Prevention of Acute GVHD Following Myeloablative Allogeneic HSCT |
https://ClinicalTrials.gov/show/NCT02663622 |
Active, not recruiting |
OncoImmune, Inc. |
2020-11-30 |
| NCT02660684 |
Study to Assess the Safety and Efficacy of Tacrolimus (Prograf Capsule/Injection) and Methotrexate (MTX) Combination Therapy for Prevention of Graft Versus Host Disease (GVHD) in Patients Who Received Peripheral Hematopoietic Stem Cell Transplantation From a Sibling Donor |
https://ClinicalTrials.gov/show/NCT02660684 |
Completed |
Astellas Pharma Inc |
2010-02-28 |
| NCT02659657 |
Prophylaxis Roles of IL-2 Treatment on GVHD After Transplantation |
https://ClinicalTrials.gov/show/NCT02659657 |
Recruiting |
Peking University People’s Hospital |
2020-06-30 |
| NCT02652130 |
Safety Follow-up of Treatment With Remestemcel-L in Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD |
https://ClinicalTrials.gov/show/NCT02652130 |
Completed |
Mesoblast, Ltd. |
2018-06-15 |
| NCT02641236 |
Gut Decontamination In Pediatric Allogeneic Hematopoietic |
https://ClinicalTrials.gov/show/NCT02641236 |
Recruiting |
Dana-Farber Cancer Institute |
2021-04-30 |
| NCT02614612 |
Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHD |
https://ClinicalTrials.gov/show/NCT02614612 |
Completed |
Incyte Corporation |
2016-06-30 |
| NCT02913261 |
Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT02913261 |
Active, not recruiting |
Novartis |
2019-06-24 |
| NCT02891603 |
A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression |
https://ClinicalTrials.gov/show/NCT02891603 |
Recruiting |
H. Lee Moffitt Cancer Center and Research Institute |
2020-12-31 |
| NCT02867800 |
Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease |
https://ClinicalTrials.gov/show/NCT02867800 |
Active, not recruiting |
Columbia University |
2021-06-30 |
| NCT02588339 |
Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention |
https://ClinicalTrials.gov/show/NCT02588339 |
Active, not recruiting |
H. Lee Moffitt Cancer Center and Research Institute |
2018-12-07 |
| NCT02340676 |
A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory cGVHD |
https://ClinicalTrials.gov/show/NCT02340676 |
Active, not recruiting |
Dana-Farber Cancer Institute |
2017-08-31 |
| NCT01937468 |
Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease |
https://ClinicalTrials.gov/show/NCT01937468 |
Active, not recruiting |
Dana-Farber Cancer Institute |
2017-08-31 |
| NCT01366092 |
Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease |
https://ClinicalTrials.gov/show/NCT01366092 |
Active, not recruiting |
Dana-Farber Cancer Institute |
2014-10-31 |
| NCT02513498 |
Ixazomib Citrate in Treating Patients With Chronic Graft-versus-Host Disease |
https://ClinicalTrials.gov/show/NCT02513498 |
Completed |
Fred Hutchinson Cancer Research Center |
2018-01-05 |
| NCT02511782 |
Transdermal Patch to Monitor Inflammatory Biomarkers of GVHD |
https://ClinicalTrials.gov/show/NCT02511782 |
Completed |
Children’s Hospital Medical Center, Cincinnati |
2014-06-30 |
| NCT02491359 |
Carfilzomib in Treating Patients With Chronic Graft-Versus-Host Disease |
https://ClinicalTrials.gov/show/NCT02491359 |
Completed |
Fred Hutchinson Cancer Research Center |
2018-02-19 |
| NCT02483702 |
Irradiated Blood Versus Non Irradiated Blood Transfusions in Craniosynostosis Repair |
https://ClinicalTrials.gov/show/NCT02483702 |
Completed |
Valley Anesthesiology Consultants |
2017-05-11 |
| NCT02423915 |
Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention |
https://ClinicalTrials.gov/show/NCT02423915 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2020-12-30 |
| NCT02027805 |
Safety and Efficacy Study of T-Guard to Treat Steroid-resistant Acute GVHD |
https://ClinicalTrials.gov/show/NCT02027805 |
Completed |
Xenikos |
2016-09-07 |
| NCT02406651 |
Study of IL-22 IgG2-Fc (F-652) for Subjects With Grade II-IV Lower GI aGVHD |
https://ClinicalTrials.gov/show/NCT02406651 |
Active, not recruiting |
Generon (Shanghai) Corporation Ltd. |
2019-04-09 |
| NCT02386800 |
CINC424A2X01B Rollover Protocol |
https://ClinicalTrials.gov/show/NCT02386800 |
Recruiting |
Novartis |
2025-09-17 |
| NCT02359929 |
BMT Autologous MSCs for GvHD |
https://ClinicalTrials.gov/show/NCT02359929 |
Recruiting |
Emory University |
2020-11-30 |
| NCT02345850 |
Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301) |
https://ClinicalTrials.gov/show/NCT02345850 |
Active, not recruiting |
National Heart, Lung, and Blood Institute (NHLBI) |
2020-09-30 |
| NCT02342613 |
Adoptive Immunotherapy With Activated Marrow Infiltrating Lymphocytes and Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation |
https://ClinicalTrials.gov/show/NCT02342613 |
Recruiting |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2023-01-31 |
| NCT02337595 |
Memory T-cell Infusion to Improve Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT02337595 |
Completed |
Federal Research Institute of Pediatric Hematology, Oncology and Immunology |
2015-03-31 |
| NCT02250300 |
MLN9708 for the Prophylaxis of Chronic Graft-versus-host Disease in Patient Undergoing Allogeneic Transplantation |
https://ClinicalTrials.gov/show/NCT02250300 |
Active, not recruiting |
Medical College of Wisconsin |
2021-09-30 |
| NCT02248597 |
Donor Stem Cell Transplant Followed by Cyclophosphamide in Treating Patients With Hematological Diseases |
https://ClinicalTrials.gov/show/NCT02248597 |
Recruiting |
Wake Forest University Health Sciences |
2020-09-30 |
| NCT02208037 |
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) |
https://ClinicalTrials.gov/show/NCT02208037 |
Completed |
National Heart, Lung, and Blood Institute (NHLBI) |
2017-10-31 |
| NCT02206035 |
Phase II Open-Label Trial of Tacrolimus/Methotrexate and Tocilizumab for the Prevention of Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT02206035 |
Completed |
Medical College of Wisconsin |
2018-09-30 |
| NCT02195869 |
Study of the Bruton’s Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease |
https://ClinicalTrials.gov/show/NCT02195869 |
Completed |
Pharmacyclics LLC. |
2017-09-15 |
| NCT02193880 |
Safety of Post-transplant Alpha-beta Depleted T-cell Infusion Following Haploidentical Stem Cell Transplant (Haplo SCT) |
https://ClinicalTrials.gov/show/NCT02193880 |
Completed |
University of Alabama at Birmingham |
2018-03-13 |
| NCT02176031 |
Phase II Trial of Natalizumab + Prednisone for Initial Therapy of Acute GI GVHD |
https://ClinicalTrials.gov/show/NCT02176031 |
Completed |
Dana-Farber Cancer Institute |
2019-02-28 |
| NCT02172768 |
Pharmacokinetics of Micafungin Given Twice Weekly Intravenously Compared to Micafungin Given Daily to Patients at Risk for Developing an Invasive Fungal Disease |
https://ClinicalTrials.gov/show/NCT02172768 |
Completed |
Radboud University |
2016-06-30 |
| NCT02145403 |
Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT02145403 |
Active, not recruiting |
University of Michigan Rogel Cancer Center |
2018-11-26 |
| NCT02144701 |
Lactobacillus Rhamnosus GG in Reducing Incidence of Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT02144701 |
Completed |
Rutgers, The State University of New Jersey |
2016-02-28 |
| NCT02144025 |
Prevention of Ocular Graft-Versus-Host Disease With Topical Cyclosporine in Recipients of Allogeneic HSCT |
https://ClinicalTrials.gov/show/NCT02144025 |
Completed |
Hospital Universitario Dr. Jose E. Gonzalez |
2016-02-29 |
| NCT02133924 |
Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease |
https://ClinicalTrials.gov/show/NCT02133924 |
Recruiting |
Icahn School of Medicine at Mount Sinai |
2020-12-31 |
| NCT02117115 |
Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT02117115 |
Completed |
Washington University School of Medicine |
2014-10-31 |
| NCT02105766 |
Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure |
https://ClinicalTrials.gov/show/NCT02105766 |
Recruiting |
National Institutes of Health Clinical Center (CC) |
2021-08-31 |
| NCT01318330 |
Safety Study of Homeo-GH (Bone Marrow Derived Clonal Mesenchymal Stem Cell) to Treat Acute/Chronic Graft Versus Host Disease (GVHD) |
https://ClinicalTrials.gov/show/NCT01318330 |
Completed |
HomeoTherapy Co., Ltd |
2011-12-31 |
| NCT01309997 |
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease |
https://ClinicalTrials.gov/show/NCT01309997 |
Completed |
Fred Hutchinson Cancer Research Center |
2014-12-31 |
| NCT01287078 |
Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans |
https://ClinicalTrials.gov/show/NCT01287078 |
Completed |
National Institutes of Health Clinical Center (CC) |
2018-08-08 |
| NCT01273207 |
Extension Study (Extended Access) of Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans |
https://ClinicalTrials.gov/show/NCT01273207 |
Completed |
National Institutes of Health Clinical Center (CC) |
2019-05-10 |
| NCT02040623 |
Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2) |
https://ClinicalTrials.gov/show/NCT02040623 |
Completed |
Rigel Pharmaceuticals |
2016-07-31 |
| NCT02032446 |
Umbilical Cord Derived Mesenchymal Stromal Cells For The Treatment of Severe Steroid-resistant Graft Versus Host Disease |
https://ClinicalTrials.gov/show/NCT02032446 |
Recruiting |
A.O. Ospedale Papa Giovanni XXIII |
2016-09-30 |
| NCT03591874 |
Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease |
https://ClinicalTrials.gov/show/NCT03591874 |
Completed |
Ocugen |
2020-06-15 |
| NCT03339297 |
An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD) |
https://ClinicalTrials.gov/show/NCT03339297 |
Completed |
Jazz Pharmaceuticals |
2020-05-12 |
| NCT00529035 |
Ultra-Low Dose Interleukin-2 for Refractory Chronic Graft Versus Host Disease |
https://ClinicalTrials.gov/show/NCT00529035 |
Completed |
Dana-Farber Cancer Institute |
2011-06-30 |
| NCT01977781 |
Safety and Efficacy of Topical Tacrolimus 0.05% in the Treatment of Ocular Graft-Versus-Host Disease |
https://ClinicalTrials.gov/show/NCT01977781 |
Completed |
Massachusetts Eye and Ear Infirmary |
2014-09-30 |
| NCT01956903 |
Treatment of Refractory Acute Graft-Versus-Host Disease by Sequential Infusion of Allogenic Mesenchymal Stem Cell. |
https://ClinicalTrials.gov/show/NCT01956903 |
Completed |
Grupo Espanol de trasplantes hematopoyeticos y terapia celular |
2013-09-30 |
| NCT01954979 |
A Phase I Study of Abatacept in the Treatment of Patients With Steroid Refractory Chronic Graft Versus Host Disease (cGVHD) |
https://ClinicalTrials.gov/show/NCT01954979 |
Recruiting |
Dana-Farber Cancer Institute |
2020-06-30 |
| NCT01950507 |
Evaluation of Budesonide and How It Interacts With Antifungal Drugs in People With Gastrointestinal Graft-Versus-Host Disease |
https://ClinicalTrials.gov/show/NCT01950507 |
Completed |
National Institutes of Health Clinical Center (CC) |
2018-05-10 |
| NCT01927120 |
In Vivo Treg Expansion and Graft-Versus-Host Disease Prophylaxis |
https://ClinicalTrials.gov/show/NCT01927120 |
Completed |
H. Lee Moffitt Cancer Center and Research Institute |
2016-08-25 |
| NCT01926899 |
A Multicenter Phase I Study Evaluating the Addition of Bortezomib to an Established Acute Graft Versus Host Disease Prophylaxis Regimen in Pediatric Allogeneic Hematopoietic Stem Cell Transplant Patients |
https://ClinicalTrials.gov/show/NCT01926899 |
Completed |
Indiana University |
2018-02-01 |
| NCT01903473 |
Donor Regulatory T Cells Infusion in Patients With Chronic Graft-versus-host Disease (GVHD) |
https://ClinicalTrials.gov/show/NCT01903473 |
Recruiting |
University of Liege |
2021-06-30 |
| NCT01898377 |
Imatinib Mesylate and Mycophenolate Mofetil for Steroid-Refractory Sclerotic/Fibrotic cGVHD in Children |
https://ClinicalTrials.gov/show/NCT01898377 |
Active, not recruiting |
Seoul National University Hospital |
2018-07-31 |
| NCT01883180 |
ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis |
https://ClinicalTrials.gov/show/NCT01883180 |
Completed |
Nanfang Hospital of Southern Medical University |
2017-09-30 |
| NCT01862965 |
Treatment of Newly Diagnosed Moderate or Severe Chronic Graft-versus-host Disease With Prednisone and Everolimus |
https://ClinicalTrials.gov/show/NCT01862965 |
Completed |
Universitätsklinikum Hamburg-Eppendorf |
2018-02-07 |
| NCT01810718 |
Phase I/II for Safety and Efficacy of Nilotinib in a Population Steroid-refractory/or Steroid-dependent cGVHD |
https://ClinicalTrials.gov/show/NCT01810718 |
Completed |
Gruppo Italiano Trapianto di Midollo Osseo |
2015-02-28 |
| NCT01804686 |
A Long-term Extension Study of PCI-32765 (Ibrutinib) |
https://ClinicalTrials.gov/show/NCT01804686 |
Enrolling by invitation |
Janssen Research & Development, LLC |
2026-12-31 |
| NCT01795573 |
Ex-vivo Expanded Donor Regulatory T Cells for Prevention of Acute Graft-Versus-Host Disease |
https://ClinicalTrials.gov/show/NCT01795573 |
Active, not recruiting |
H. Lee Moffitt Cancer Center and Research Institute |
2020-12-31 |
| NCT01790568 |
Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT01790568 |
Completed |
University of Michigan Rogel Cancer Center |
2017-01-01 |
| NCT01789255 |
Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT01789255 |
Completed |
National Cancer Institute (NCI) |
2014-03-31 |
| NCT01788501 |
Tacrolimus/Methotrexate Versus Cyclosporine/Methotrexate for Prophylaxis of Graft Versus Host Disease |
https://ClinicalTrials.gov/show/NCT01788501 |
Completed |
Seoul National University Hospital |
2017-03-01 |
| NCT01754389 |
Standard of Care vs. Bortezomib in Graft-Versus Host Disease After Hematopoietic Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT01754389 |
Completed |
Dana-Farber Cancer Institute |
2016-05-31 |
| NCT01743131 |
Abatacept as GVHD Prophylaxis Phase 2 |
https://ClinicalTrials.gov/show/NCT01743131 |
Active, not recruiting |
Boston Children’s Hospital |
2018-06-30 |
| NCT01713400 |
Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease |
https://ClinicalTrials.gov/show/NCT01713400 |
Completed |
H. Lee Moffitt Cancer Center and Research Institute |
2014-10-27 |
| NCT01700036 |
A Pilot Study of Alpha-1-Antitrypsin (AAT) in Steroid Refractory Acute Graft vs Host Disease |
https://ClinicalTrials.gov/show/NCT01700036 |
Completed |
University of Michigan Rogel Cancer Center |
2016-10-31 |
| NCT01699412 |
Clinical Trial With Clobetasol and Dexamethasone for Topical Treatment of Oral Lesions of Chronic Graft-versus-host Disease |
https://ClinicalTrials.gov/show/NCT01699412 |
Completed |
Grupo de Estudos Multicentricos em Onco-Hematologia |
2012-07-31 |
| NCT01695668 |
Treatment of Ocular Graft-versus-Host Disease (GVHD) With Topical Loteprednol Etabonate 0.5% |
https://ClinicalTrials.gov/show/NCT01695668 |
Completed |
University of Michigan |
2013-09-30 |
| NCT01688466 |
Pomalidomide for Chronic Graft-versus-Host Disease |
https://ClinicalTrials.gov/show/NCT01688466 |
Completed |
National Institutes of Health Clinical Center (CC) |
2017-03-30 |
| NCT01680965 |
Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease |
https://ClinicalTrials.gov/show/NCT01680965 |
Active, not recruiting |
H. Lee Moffitt Cancer Center and Research Institute |
2020-09-30 |
| NCT01672229 |
Bortezomib in Patients With Chronic Graft Versus Host Disease |
https://ClinicalTrials.gov/show/NCT01672229 |
Completed |
University of California, Davis |
2018-04-09 |
| NCT01665677 |
Atorvastatin as GVHD Prophylaxis for Allogeneic Hematopoietic Cell Transplantation |
https://ClinicalTrials.gov/show/NCT01665677 |
Active, not recruiting |
Medical College of Wisconsin |
2023-12-31 |
| NCT01633229 |
Bone Marrow Stromal Cell Infusions for Stem Cell Transplant Complications |
https://ClinicalTrials.gov/show/NCT01633229 |
Completed |
National Institutes of Health Clinical Center (CC) |
2013-07-01 |
| NCT01616056 |
Bandage Lenses in Treating Patients With Ocular Graft-Versus-Host Disease |
https://ClinicalTrials.gov/show/NCT01616056 |
Completed |
Fred Hutchinson Cancer Research Center |
2014-10-31 |
| NCT01596218 |
Brentuximab Vedotin for Steroid Refractory GvHD |
https://ClinicalTrials.gov/show/NCT01596218 |
Completed |
Massachusetts General Hospital |
2016-06-30 |
| NCT01557517 |
Clobetasol for Oral Graft-Versus-Host Disease |
https://ClinicalTrials.gov/show/NCT01557517 |
Completed |
National Institutes of Health Clinical Center (CC) |
2017-06-09 |
| NCT01523821 |
Alpha 1 Anti-Trypsin (AAT) in Treating Patients With Acute Graft-Versus-Host Disease GVHD) |
https://ClinicalTrials.gov/show/NCT01523821 |
Completed |
Fred Hutchinson Cancer Research Center |
2017-01-15 |
| NCT01520623 |
Complement and Graft-versus-host Disease |
https://ClinicalTrials.gov/show/NCT01520623 |
Completed |
Assistance Publique - Hôpitaux de Paris |
2013-02-28 |
| NCT01509560 |
PhaseII,Open-label,Pilot Study Evaluating the Safety+Efficacy of Certican ® in the Prevention of Chronic Graft-versus-host Disease+Late Pulmonary Complications After Allogeneic Hematopoietic Cell Transplantation Blood |
https://ClinicalTrials.gov/show/NCT01509560 |
Completed |
Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH |
2016-04-30 |
| NCT01491958 |
Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT01491958 |
Completed |
Ohio State University Comprehensive Cancer Center |
2014-01-01 |
| NCT01487577 |
Pharmacokinetics-based Mycophenolate Mofetil Dosing for GVHD Prevention |
https://ClinicalTrials.gov/show/NCT01487577 |
Completed |
University of Pittsburgh |
2014-12-31 |
| NCT01463475 |
University of Wisconsin hMSC Cell Bank: Bone Marrow Donor Protocol |
https://ClinicalTrials.gov/show/NCT01463475 |
Completed |
University of Wisconsin, Madison |
2013-12-31 |
| NCT01428973 |
Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens |
https://ClinicalTrials.gov/show/NCT01428973 |
Active, not recruiting |
University of Liege |
2022-09-30 |
| NCT01427881 |
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT01427881 |
Completed |
Fred Hutchinson Cancer Research Center |
2014-06-30 |
| NCT01393132 |
Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye |
https://ClinicalTrials.gov/show/NCT01393132 |
Completed |
Michigan Cornea Consultants, PC |
2012-12-31 |
| NCT01380535 |
Extracorporeal Photopheresis (ECP) With Methoxsalen for Chronic Graft Versus Host Disease (cGVHD) |
https://ClinicalTrials.gov/show/NCT01380535 |
Completed |
Mallinckrodt |
2015-03-31 |
| NCT01379209 |
Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT) |
https://ClinicalTrials.gov/show/NCT01379209 |
Completed |
Regimmune Corporation |
2015-06-30 |
| NCT01324908 |
Biomarkers in Predicting Response in Patients With Graft-Versus-Host Disease Undergoing Extracorporeal Photophoresis |
https://ClinicalTrials.gov/show/NCT01324908 |
Active, not recruiting |
Vanderbilt-Ingram Cancer Center |
2018-01-31 |
| NCT04204122 |
Vigamox Treatment for Ocular Graft-Versus-Host Disease |
https://ClinicalTrials.gov/show/NCT04204122 |
Recruiting |
Washington University School of Medicine |
2022-07-31 |
| NCT04337515 |
A Feasibility Study Using CLINIMACS® for Alpha/Beta T-Cell Depletion in Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT04337515 |
Recruiting |
University of California, San Francisco |
2022-01-01 |
| NCT04291261 |
Extracorporal Photopheresis With UVADEX Plus Standard Steroid Treatment for High Risk Acute Graft-versus-host Disease |
https://ClinicalTrials.gov/show/NCT04291261 |
Active, not recruiting |
Universitätsklinikum Hamburg-Eppendorf |
2023-01-31 |
| NCT04290429 |
Treatment of Patients With Teduglutide (GLP-2) for GVHD and Analysis of Paneth Cells of GVHD Patients |
https://ClinicalTrials.gov/show/NCT04290429 |
Completed |
University of Freiburg |
2019-12-06 |
| NCT04285424 |
FMT for Steroid Resistant Gut Acute GVHD |
https://ClinicalTrials.gov/show/NCT04285424 |
Recruiting |
Affiliated Hospital to Academy of Military Medical Sciences |
2021-12-31 |
| NCT04235036 |
Ibrutinib and Rituxan for Chronic GVHD |
https://ClinicalTrials.gov/show/NCT04235036 |
Recruiting |
Northside Hospital, Inc. |
2021-12-31 |
| NCT04227938 |
Study of ALPN-101 in Steroid-resistant or Steroid-refractory Acute GVHD Versus Host Disease |
https://ClinicalTrials.gov/show/NCT04227938 |
Recruiting |
Alpine Immune Sciences, Inc. |
2022-05-31 |
| NCT04212416 |
Leflunomide in Treating Patients With Steroid Dependent Chronic Graft Versus Host Disease |
https://ClinicalTrials.gov/show/NCT04212416 |
Recruiting |
City of Hope Medical Center |
2021-08-02 |
| NCT04200365 |
A Study of Itacitinib for the Treatment of Chronic Graft Versus Host Disease (cGVHD) |
https://ClinicalTrials.gov/show/NCT04200365 |
Recruiting |
SCRI Development Innovations, LLC |
2023-06-30 |
| NCT04189432 |
Efficacy and Safety of SCM-CGH in Patients With Steroid-Refractory or Dependent Chronic Graft-Versus-Host Disease |
https://ClinicalTrials.gov/show/NCT04189432 |
Recruiting |
SCM Lifescience Co., LTD. |
2021-03-31 |
| NCT04131738 |
Baricitinib for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell Transplantation |
https://ClinicalTrials.gov/show/NCT04131738 |
Recruiting |
Washington University School of Medicine |
2021-07-31 |
| NCT04111497 |
Glasdegib for Chronic Graft-Versus-Host Disease |
https://ClinicalTrials.gov/show/NCT04111497 |
Recruiting |
Fred Hutchinson Cancer Research Center |
2022-12-31 |
| NCT04014790 |
RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT04014790 |
Recruiting |
Regimmune Corporation |
2021-08-31 |
| NCT04014413 |
Safety and Efficacy of Fecal Microbiota Transplantation |
https://ClinicalTrials.gov/show/NCT04014413 |
Recruiting |
Chinese University of Hong Kong |
2023-10-31 |
| NCT03990051 |
Treatment Safety and Efficacy of Pro-ocularâ„¢ 1% for Chronic Ocular Graft Following Allogeneic HSCT. |
https://ClinicalTrials.gov/show/NCT03990051 |
Enrolling by invitation |
Glia, LLC |
2019-10-21 |
| NCT03983850 |
Optimizing PTCy Dose and Timing |
https://ClinicalTrials.gov/show/NCT03983850 |
Recruiting |
National Institutes of Health Clinical Center (CC) |
2024-05-31 |
| NCT03963024 |
Treosulfan-TMI Conditioning and Rapamycin GvHD Prophylaxis Before Allo-HSCT |
https://ClinicalTrials.gov/show/NCT03963024 |
Recruiting |
IRCCS San Raffaele |
2019-12-31 |
| NCT03954236 |
Study of the Safety and Efficacy of Ruxolitinib Cream for Non-Sclerotic Chronic Cutaneous Graft-Versus-Host Disease |
https://ClinicalTrials.gov/show/NCT03954236 |
Recruiting |
Memorial Sloan Kettering Cancer Center |
2021-05-31 |
| NCT03945591 |
High-Dose Post-Transplant Cyclophosphamide and Bortezomib (CyBor) for the Prevention of Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) |
https://ClinicalTrials.gov/show/NCT03945591 |
Recruiting |
NYU Langone Health |
2022-11-30 |
| NCT03924401 |
Acute GVHD Suppression Using Costimulation Blockade to Expand Non-malignant Transplant |
https://ClinicalTrials.gov/show/NCT03924401 |
Recruiting |
Emory University |
2023-12-31 |
| NCT03918343 |
Lipopolysaccharide Metabolism and Identification of Potential Biomarkers Predictive of Graft-versus-host Disease After Allogeneic Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT03918343 |
Recruiting |
Centre Hospitalier Universitaire de Besancon |
2021-11-30 |
| NCT03847844 |
UCMSCs as Front-line Approach of Treatment for Patients With aGVHD |
https://ClinicalTrials.gov/show/NCT03847844 |
Recruiting |
Cytopeutics Sdn. Bhd. |
2021-10-31 |
| NCT03846479 |
Itacitinib for Low Risk GVHD |
https://ClinicalTrials.gov/show/NCT03846479 |
Recruiting |
Icahn School of Medicine at Mount Sinai |
2020-12-31 |
| NCT03842696 |
Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation |
https://ClinicalTrials.gov/show/NCT03842696 |
Recruiting |
University of Michigan Rogel Cancer Center |
2024-02-29 |
| NCT03839069 |
Minor Salivary Gland Transplantation for Cicatrizing Conjunctivitis |
https://ClinicalTrials.gov/show/NCT03839069 |
Recruiting |
National Taiwan University Hospital |
2020-12-31 |
| NCT03836690 |
Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT03836690 |
Recruiting |
University College, London |
2022-07-01 |
| NCT03818334 |
Post Transplant Cyclophosphamide in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT03818334 |
Recruiting |
Hospital Israelita Albert Einstein |
2021-11-01 |
| NCT03805789 |
The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft‑Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant |
https://ClinicalTrials.gov/show/NCT03805789 |
Recruiting |
CSL Behring |
2022-08-31 |
| NCT03790332 |
Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD) |
https://ClinicalTrials.gov/show/NCT03790332 |
Recruiting |
Pharmacyclics LLC. |
2021-09-09 |
| NCT03779854 |
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT03779854 |
Recruiting |
Fred Hutchinson Cancer Research Center |
2022-12-31 |
| NCT03717480 |
Ex Vivo TCR αβ T Cell Depletion for Graft-Versus-Host Disease Prophylaxis in Mismatched Donor Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT03717480 |
Recruiting |
Dana-Farber Cancer Institute |
2022-05-01 |
| NCT03689894 |
Ibrutinib Plus Rituximab for cGVHD Following Allo-SCT |
https://ClinicalTrials.gov/show/NCT03689894 |
Recruiting |
Dartmouth-Hitchcock Medical Center |
2023-12-31 |
| NCT03689465 |
PTCy-ATG vs ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis |
https://ClinicalTrials.gov/show/NCT03689465 |
Recruiting |
Nanfang Hospital of Southern Medical University |
2020-09-30 |
| NCT03683498 |
Donor Regulatory T-cells for Steroid-Refractory Chronic Graft-versus-host-Disease |
https://ClinicalTrials.gov/show/NCT03683498 |
Recruiting |
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla |
2019-08-31 |
| NCT03657160 |
Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation |
https://ClinicalTrials.gov/show/NCT03657160 |
Recruiting |
Takeda |
2020-10-23 |
| NCT03616184 |
Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic Glucocorticoids |
https://ClinicalTrials.gov/show/NCT03616184 |
Recruiting |
University of Nebraska |
2023-04-30 |
| NCT03605927 |
CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease |
https://ClinicalTrials.gov/show/NCT03605927 |
Recruiting |
H. Lee Moffitt Cancer Center and Research Institute |
2024-01-31 |
| NCT03604692 |
A Phase 1/2 Study to Evaluate SNDX- 6352 in Subjects With Active cGVHD |
https://ClinicalTrials.gov/show/NCT03604692 |
Recruiting |
Syndax Pharmaceuticals |
2020-12-01 |
| NCT03584516 |
GRAVITAS-309: Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease |
https://ClinicalTrials.gov/show/NCT03584516 |
Recruiting |
Incyte Corporation |
2023-08-17 |
| NCT03546556 |
18-FLT PET/MR Imaging to Predict Graft Failure and GVHD in Bone Marrow Transplant Patients |
https://ClinicalTrials.gov/show/NCT03546556 |
Recruiting |
UNC Lineberger Comprehensive Cancer Center |
2020-12-31 |
| NCT03497273 |
Safety of Itacitinib in Combination With Corticosteroids for Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in Japanese Subjects |
https://ClinicalTrials.gov/show/NCT03497273 |
Completed |
Incyte Corporation |
2019-11-30 |
| NCT03491215 |
Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease |
https://ClinicalTrials.gov/show/NCT03491215 |
Recruiting |
Novartis |
2022-12-26 |
| NCT03483675 |
Discontinuation or Continuation of Immunosuppressive Therapy in Participants With Chronic Graft Versus Host Disease |
https://ClinicalTrials.gov/show/NCT03483675 |
Active, not recruiting |
Fred Hutchinson Cancer Research Center |
2020-05-14 |
| NCT03474679 |
A Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD) |
https://ClinicalTrials.gov/show/NCT03474679 |
Active, not recruiting |
Janssen Pharmaceutical K.K. |
2022-02-28 |
| NCT03459040 |
A Proof of Concept Pilot Trial of Alpha-1-Antitrypsin for Pre-Emption Of Steroid-Refractory Acute GVHD |
https://ClinicalTrials.gov/show/NCT03459040 |
Active, not recruiting |
Icahn School of Medicine at Mount Sinai |
2020-07-31 |
| NCT03434730 |
Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation |
https://ClinicalTrials.gov/show/NCT03434730 |
Recruiting |
Memorial Sloan Kettering Cancer Center |
2021-02-07 |
| NCT03434704 |
Peripheral Blood Stem Cell Transplantation From Family Haploidentical Donors in Patients With Myelodysplastic Syndrome and Acute Leukemia Under Primary Prophylaxis With Posaconazole |
https://ClinicalTrials.gov/show/NCT03434704 |
Recruiting |
IRCCS San Raffaele |
2020-03-15 |
| NCT03422627 |
Safety and Efficacy of AMG 592 in Subjects With Steroid Refractory Chronic Graft Versus Host Disease |
https://ClinicalTrials.gov/show/NCT03422627 |
Recruiting |
Amgen |
2023-05-22 |
| NCT03415867 |
Glasdegib in Refractory Patients With Sclerotic Chronic Graft-Versus-Host Disease |
https://ClinicalTrials.gov/show/NCT03415867 |
Active, not recruiting |
Grupo Espanol de trasplantes hematopoyeticos y terapia celular |
2023-01-09 |
| NCT03414645 |
Topical Fibrinogen-Depleted Human Platelet Lysate in Patients With Dry Eye Secondary to Graft vs. Host Disease |
https://ClinicalTrials.gov/show/NCT03414645 |
Recruiting |
Cambium Medical Technologies LLC |
2019-09-30 |
| NCT01240525 |
Donor Lymphocyte Infusion After Stem Cell Transplant in Treating Patients With Haematological Cancers |
https://ClinicalTrials.gov/show/NCT01240525 |
Active, not recruiting |
University College, London |
2019-11-30 |
| NCT01233921 |
Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT01233921 |
Completed |
Fred Hutchinson Cancer Research Center |
2012-07-31 |
| NCT01222039 |
Multicenter Clinical Trial for the Evaluation of Mesenchymal Stem Cells From Adipose Tissue in Patients With Chronic Graft Versus Host Disease. |
https://ClinicalTrials.gov/show/NCT01222039 |
Completed |
Andalusian Network for Design and Translation of Advanced Therapies |
2014-06-30 |
| NCT01188798 |
Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01188798 |
Completed |
St. Jude Children’s Research Hospital |
2012-02-29 |
| NCT01175148 |
Atorvastatin for the Prophylaxis of Acute GVHD in Patients Undergoing Matched Sibling Allogeneic Transplantation |
https://ClinicalTrials.gov/show/NCT01175148 |
Completed |
West Virginia University |
2014-12-31 |
| NCT01174940 |
Test Extracorporeal Photopheresis (ECP) Treatment Before/After Allogeneic Bone Marrow Transplant (BMT) or Peripheral Blood Stem Cell (PBSC) Transplant to Prevent Graft Versus Host Disease |
https://ClinicalTrials.gov/show/NCT01174940 |
Completed |
University of Kansas Medical Center |
2014-08-31 |
| NCT01161628 |
Rituximab for the Primary Treatment of Denovo Extensive Chronic Graft Versus Host Disease (GVHD) |
https://ClinicalTrials.gov/show/NCT01161628 |
Completed |
Northside Hospital, Inc. |
2014-01-31 |
| NCT01155817 |
Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease |
https://ClinicalTrials.gov/show/NCT01155817 |
Completed |
Stanford University |
2013-12-31 |
| NCT01135641 |
Study of First Line Treatment of Chronic Graft Versus Host Disease With the Association of Ciclosporine, Corticosteroids and Rituximab (Protocol R-GVHD) |
https://ClinicalTrials.gov/show/NCT01135641 |
Completed |
Nantes University Hospital |
2014-03-31 |
| NCT01111526 |
Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease (GVHD) |
https://ClinicalTrials.gov/show/NCT01111526 |
Completed |
H. Lee Moffitt Cancer Center and Research Institute |
2015-10-31 |
| NCT01106833 |
Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801) |
https://ClinicalTrials.gov/show/NCT01106833 |
Completed |
Medical College of Wisconsin |
2017-02-14 |
| NCT01042509 |
Combination of Alemtuzumab and Rituximab at Low-doses in Refractory Chronic Graft-Versus-Host Disease |
https://ClinicalTrials.gov/show/NCT01042509 |
Completed |
Hospital Universitario Dr. Jose E. Gonzalez |
2011-10-31 |
| NCT01002742 |
Acute Graft-versus-Host Disease Treatment (BMT CTN 0802) |
https://ClinicalTrials.gov/show/NCT01002742 |
Completed |
Medical College of Wisconsin |
2012-01-31 |
| NCT00993343 |
Randomized Trial Comparing Sirolimus and Tacrolimus Versus Cyclosporine and Methotrexate as Graft-versus-host Disease (GVHD) Prophylaxis After Allogeneic Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT00993343 |
Completed |
Karolinska Institutet |
2015-02-28 |
| NCT00967096 |
Rifaximin for Preventing Acute Graft Versus Host Disease (AGVHD) |
https://ClinicalTrials.gov/show/NCT00967096 |
Completed |
Emory University |
2009-04-30 |
| NCT00948753 |
Maraviroc in Patients Undergoing Non-Myeloablative Allogeneic Stem-Cell Transplantation |
https://ClinicalTrials.gov/show/NCT00948753 |
Completed |
Abramson Cancer Center of the University of Pennsylvania |
2011-04-30 |
| NCT00948727 |
Cyclosporine Dose Adjustment According to Calcineurin Activity After Allogeneic Hematopoietic Stem-cell Transplantation |
https://ClinicalTrials.gov/show/NCT00948727 |
Completed |
Assistance Publique - Hôpitaux de Paris |
2006-09-30 |
| NCT00929695 |
Low-Dose Prednisone or Methylprednisolone in Treating Patients With Newly Diagnosed Acute Graft-versus-Host Disease |
https://ClinicalTrials.gov/show/NCT00929695 |
Completed |
Fred Hutchinson Cancer Research Center |
2013-07-31 |
| NCT00923845 |
Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer |
https://ClinicalTrials.gov/show/NCT00923845 |
Completed |
National Institutes of Health Clinical Center (CC) |
2015-06-01 |
| NCT00914940 |
Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD |
https://ClinicalTrials.gov/show/NCT00914940 |
Completed |
Fred Hutchinson Cancer Research Center |
2019-12-01 |
| NCT00887263 |
Efficacy and Safety Study of Budesonide to Treat Oral Chronic Graft vs Host Disease (cGvHD) |
https://ClinicalTrials.gov/show/NCT00887263 |
Completed |
Dr. Falk Pharma GmbH |
2015-10-31 |
| NCT03297528 |
Chemotherapy and DLI for Prevention of Second Relapse in Patients With Relapsed Acute Leukemia After Allotransplant |
https://ClinicalTrials.gov/show/NCT03297528 |
Recruiting |
Peking University People’s Hospital |
2020-10-01 |
| NCT00827398 |
Treatment of Steroid Resistant GVHD by Infusion MSC |
https://ClinicalTrials.gov/show/NCT00827398 |
Completed |
UMC Utrecht |
2013-07-31 |
| NCT00824889 |
Exploratory Study of Natural Killer Cells in Human Skin |
https://ClinicalTrials.gov/show/NCT00824889 |
Completed |
Assistance Publique Hopitaux De Marseille |
2011-11-30 |
| NCT03819803 |
Fecal Microbiota Transplantation in aGvHD After ASCT |
https://ClinicalTrials.gov/show/NCT03819803 |
Recruiting |
Medical University of Graz |
2020-03-01 |
| NCT03192397 |
Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT03192397 |
Recruiting |
Roswell Park Cancer Institute |
2021-07-01 |
| NCT00815919 |
Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft Versus Host Disease |
https://ClinicalTrials.gov/show/NCT00815919 |
Completed |
Dana-Farber Cancer Institute |
2012-01-31 |
| NCT00813618 |
Study of MEDI 507 in the Treatment of Pediatric Patients |
https://ClinicalTrials.gov/show/NCT00813618 |
Completed |
MedImmune LLC |
2004-06-30 |
| NCT00810602 |
Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00810602 |
Completed |
University of Michigan Rogel Cancer Center |
2013-04-30 |
| NCT01453140 |
In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus With or Without Vidaza (Azacitidine) for Steroid-refractory Acute Graft-versus-host Disease |
https://ClinicalTrials.gov/show/NCT01453140 |
Completed |
Hackensack Meridian Health |
2012-03-31 |
| NCT00806728 |
Study of MEDI-507 in With Steroid-Resistant Acute Graft-Versus-Host Disease |
https://ClinicalTrials.gov/show/NCT00806728 |
Completed |
MedImmune LLC |
1998-11-30 |
| NCT00806208 |
Trial for Evaluation of Safety of Escalating Dose Levels of MEDI-507 in Patients for Treatment of at Least Grade II Graft-Versus-Host Disease (GvHD) |
https://ClinicalTrials.gov/show/NCT00806208 |
Completed |
MedImmune LLC |
2000-01-31 |
| NCT03764228 |
Human Amniotic Epithelial Cells Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT03764228 |
Recruiting |
Peking University People’s Hospital |
2021-07-01 |
| NCT03763318 |
A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD |
https://ClinicalTrials.gov/show/NCT03763318 |
Recruiting |
Equillium |
2021-05-31 |
| NCT00803010 |
Graft-Versus-Host Disease (GVHD) Prophylaxis After Allogeneic Peripheral Blood Hematopoietic Cell Transplantation |
https://ClinicalTrials.gov/show/NCT00803010 |
Completed |
H. Lee Moffitt Cancer Center and Research Institute |
2012-12-31 |
| NCT02525029 |
Study of Pregnyl as Adjunct Therapy for High-Risk or Refractory Acute GVHD |
https://ClinicalTrials.gov/show/NCT02525029 |
Active, not recruiting |
Masonic Cancer Center, University of Minnesota |
2021-01-31 |
| NCT03082677 |
Study of Ixazomib to Prevent Recurrent or Late Acute and Chronic Graft-versus-Host Disease 1-year After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT03082677 |
Active, not recruiting |
Memorial Sloan Kettering Cancer Center |
2021-03-31 |
| NCT02841995 |
A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host Disease |
https://ClinicalTrials.gov/show/NCT02841995 |
Active, not recruiting |
Kadmon Corporation, LLC |
2020-10-31 |
| NCT00792246 |
Voriconazole Pharmacokinetics in Children With Gastrointestinal Graft Versus Host Disease |
https://ClinicalTrials.gov/show/NCT00792246 |
Completed |
Duke University |
2012-07-31 |
| NCT00775632 |
Alemtuzumab and Cyclosporine for the Prevention of Graft vs Host Disease After Stem Cell Transplants |
https://ClinicalTrials.gov/show/NCT00775632 |
Completed |
University Health Network, Toronto |
2010-09-30 |
| NCT00770757 |
CC-4047 (Pomalidomide) for Graft vs. Host Disease |
https://ClinicalTrials.gov/show/NCT00770757 |
Completed |
Washington University School of Medicine |
2010-10-31 |
| NCT00760981 |
A Pilot Study of Imatinib Mesylate in Steroid Refractory Chronic Graft Versus Host Disease |
https://ClinicalTrials.gov/show/NCT00760981 |
Completed |
Stanford University |
2012-04-30 |
| NCT00755040 |
Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder |
https://ClinicalTrials.gov/show/NCT00755040 |
Completed |
Vanderbilt-Ingram Cancer Center |
2014-12-31 |
| NCT00726375 |
The Use of Etanercept Enbrel as Sole Treatment for Grade I Acute Graft Versus Host Disease |
https://ClinicalTrials.gov/show/NCT00726375 |
Completed |
University of Michigan Rogel Cancer Center |
2013-07-31 |
| NCT00702689 |
Imatinib Mesylate to Treat Skin Changes in Patients With Chronic Graft-Versus-Host Disease |
https://ClinicalTrials.gov/show/NCT00702689 |
Completed |
National Institutes of Health Clinical Center (CC) |
2011-05-18 |
| NCT00691015 |
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00691015 |
Completed |
Barbara Ann Karmanos Cancer Institute |
2014-04-30 |
| NCT00686855 |
Topical Dexamethasone and Tacrolimus for the Treatment of Oral Chronic Graft-Versus-Host Disease |
https://ClinicalTrials.gov/show/NCT00686855 |
Completed |
Dana-Farber Cancer Institute |
2012-12-31 |
| NCT00678275 |
Chronic Graft-versus-host Disease (cGvHD) Prophylaxis With or Without ATG Prior to Stem Cell Transplantation (SCT) From HLA-identical Siblings in Patients With Acute Leukemia |
https://ClinicalTrials.gov/show/NCT00678275 |
Completed |
Universitätsklinikum Hamburg-Eppendorf |
2014-02-28 |
| NCT00670423 |
A Study Using Tacrolimus, Sirolimus and Bortezomib as Acute Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation |
https://ClinicalTrials.gov/show/NCT00670423 |
Completed |
Indiana University |
2012-07-05 |
| NCT00656058 |
Montelukast to Treat Bronchiolitis Obliterans |
https://ClinicalTrials.gov/show/NCT00656058 |
Completed |
National Institutes of Health Clinical Center (CC) |
2014-05-02 |
| NCT00655343 |
Acute Graft-Versus-Host Disease (aGvHD) Prophylaxis With ATG-Fresenius in Matched Unrelated Donor-Stem Cell Transplantation (MUD-SCT) |
https://ClinicalTrials.gov/show/NCT00655343 |
Completed |
Neovii Biotech |
2007-03-31 |
| NCT00639717 |
Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00639717 |
Completed |
University of Michigan Rogel Cancer Center |
2012-01-31 |
| NCT00611351 |
Busulfan, Cyclophosphamide, and Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00611351 |
Completed |
University of Nebraska |
2008-02-29 |
| NCT00609609 |
Photopheresis for the Treatment of Acute Graft Versus Host Disease |
https://ClinicalTrials.gov/show/NCT00609609 |
Completed |
M.D. Anderson Cancer Center |
2016-01-31 |
| NCT00603330 |
Mesenchymal Stem Cell Infusion as Treatment for Steroid-Resistant Acute Graft Versus Host Disease (GVHD) or Poor Graft Function |
https://ClinicalTrials.gov/show/NCT00603330 |
Recruiting |
University of Liege |
2020-09-01 |
| NCT00589563 |
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer |
https://ClinicalTrials.gov/show/NCT00589563 |
Completed |
City of Hope Medical Center |
2012-02-29 |
| NCT00577278 |
Yttrium Y 90 Ibritumomab Tiuxetan, Rituximab, Indium In-111 Ibritumomab Tiuxetan, Fludarabine, Melphalan, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00577278 |
Active, not recruiting |
City of Hope Medical Center |
2019-12-31 |
| NCT00574470 |
Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD |
https://ClinicalTrials.gov/show/NCT00574470 |
Completed |
University of Iowa |
2007-11-30 |
| NCT00562497 |
Efficacy and Safety of Prochymalâ„¢ Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute Graft Versus Host Disease (GVHD) |
https://ClinicalTrials.gov/show/NCT00562497 |
Completed |
Mesoblast, Ltd. |
2009-07-14 |
| NCT00544115 |
Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders |
https://ClinicalTrials.gov/show/NCT00544115 |
Active, not recruiting |
City of Hope Medical Center |
2019-11-30 |
| NCT00513474 |
Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00513474 |
Completed |
Massachusetts General Hospital |
2013-02-12 |
| NCT00504803 |
Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-versus-host Disease |
https://ClinicalTrials.gov/show/NCT00504803 |
Completed |
University of Liege |
2010-12-31 |
| NCT00495755 |
Campath in Chronic GVHD |
https://ClinicalTrials.gov/show/NCT00495755 |
Completed |
Dana-Farber Cancer Institute |
2011-10-31 |
| NCT00492921 |
High-Dose Cyclophosphamide for Steroid Refractory GVHD |
https://ClinicalTrials.gov/show/NCT00492921 |
Completed |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2013-01-31 |
| NCT00489203 |
Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00489203 |
Completed |
Fred Hutchinson Cancer Research Center |
2010-11-30 |
| NCT00438958 |
Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases |
https://ClinicalTrials.gov/show/NCT00438958 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00423514 |
Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease |
https://ClinicalTrials.gov/show/NCT00423514 |
Active, not recruiting |
Memorial Sloan Kettering Cancer Center |
2021-11-30 |
| NCT00410657 |
Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00410657 |
Completed |
Fred Hutchinson Cancer Research Center |
2006-11-30 |
| NCT00408928 |
Study on the Safety and Effectiveness of VELCADE® in the Treatment of Graft-Versus-Host Disease |
https://ClinicalTrials.gov/show/NCT00408928 |
Completed |
Thomas Jefferson University |
2008-09-30 |
| NCT00408681 |
Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00408681 |
Completed |
Fred Hutchinson Cancer Research Center |
2010-11-30 |
| NCT00406393 |
Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) |
https://ClinicalTrials.gov/show/NCT00406393 |
Completed |
Medical College of Wisconsin |
2012-10-31 |
| NCT00397332 |
Alefacept for Chronic Graft Versus Host Disease |
https://ClinicalTrials.gov/show/NCT00397332 |
Completed |
Hadassah Medical Organization |
2013-01-31 |
| NCT00391170 |
Dexamethasone to Prevent Oral Chronic Graft-versus-Host Disease |
https://ClinicalTrials.gov/show/NCT00391170 |
Recruiting |
National Institutes of Health Clinical Center (CC) |
2023-06-30 |
| NCT00388362 |
Sirolimus as Treatment of Steroid-Refractory or Steroid-Dependent Chronic Graft-Versus-Host Disease |
https://ClinicalTrials.gov/show/NCT00388362 |
Completed |
Stanford University |
2010-11-30 |
| NCT00382109 |
Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission |
https://ClinicalTrials.gov/show/NCT00382109 |
Completed |
Children’s Oncology Group |
2011-05-31 |
| NCT00369226 |
Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT00369226 |
Completed |
Dana-Farber Cancer Institute |
2010-07-31 |
| NCT00366145 |
Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease |
https://ClinicalTrials.gov/show/NCT00366145 |
Completed |
Mesoblast, Ltd. |
2008-12-26 |
| NCT00361049 |
Donor Mesenchymal Stem Cell Infusion in Treating Patients With Acute or Chronic Graft-Versus-Host Disease After Undergoing a Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00361049 |
Completed |
Case Comprehensive Cancer Center |
2009-06-30 |
| NCT00360685 |
Tacrolimus and Mycophenolate Mofetil (MMF) in GVHD Prophylactic Regimen Compared to Tacrolimus and Methotrexate (MTX |
https://ClinicalTrials.gov/show/NCT00360685 |
Completed |
H. Lee Moffitt Cancer Center and Research Institute |
2011-01-31 |
| NCT00357084 |
Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00357084 |
Completed |
Fred Hutchinson Cancer Research Center |
2007-08-31 |
| NCT00350545 |
A Phase 2 Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft Versus Host Disease |
https://ClinicalTrials.gov/show/NCT00350545 |
Completed |
Stanford University |
2012-05-31 |
| NCT00350181 |
Sirolimus and Mycophenolate Mofetil as Graft Versus Host Disease Prophylaxis in Myeloablative Matched Related Donor Hematopoietic Cell Transplant |
https://ClinicalTrials.gov/show/NCT00350181 |
Completed |
Stanford University |
2007-08-31 |
| NCT00346359 |
Fludarabine and Busulfan Followed by Donor Peripheral Stem Cell Transplant and Antithymocyte Globulin, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Cancer |
https://ClinicalTrials.gov/show/NCT00346359 |
Completed |
Fred Hutchinson Cancer Research Center |
NA |
| NCT00284986 |
Safety and Efficacy of Prochymal for the Salvage of Treatment-Refractory Acute GVHD Patients |
https://ClinicalTrials.gov/show/NCT00284986 |
Completed |
Mesoblast, Ltd. |
2006-04-25 |
| NCT00282282 |
Tacrolimus and Sirolimus as Prophylaxis After Allogenic Non-myeloablative Peripheral Blood Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT00282282 |
Completed |
Dana-Farber Cancer Institute |
2009-01-31 |
| NCT00265837 |
Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00265837 |
Completed |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2007-08-31 |
| NCT02953678 |
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1) |
https://ClinicalTrials.gov/show/NCT02953678 |
Active, not recruiting |
Incyte Corporation |
2018-01-31 |
| NCT00255710 |
Cyclophosphamide and/or Mycophenolate Mofetil With or Without Tacrolimus in Treating Patients Who Are Undergoing a Donor Bone Marrow or Peripheral Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00255710 |
Completed |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
NA |
| NCT00248430 |
Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid Cancer |
https://ClinicalTrials.gov/show/NCT00248430 |
Completed |
Fred Hutchinson Cancer Research Center |
NA |
| NCT00248365 |
Theralux Extracorporeal Photochemotherapy (ECP) in Patients With Extensive Chronic Graft Versus Host Disease (GvHD) |
https://ClinicalTrials.gov/show/NCT00248365 |
Completed |
Kiadis Pharma |
NA |
| NCT00233896 |
Randomized Study of Oral Beclomethasone Dipropionate With Ten Days of Prednisone for Treatment of Gastrointestinal GVHD |
https://ClinicalTrials.gov/show/NCT00233896 |
Completed |
Enteron Pharmaceuticals |
NA |
| NCT00228839 |
GVH 022P: Study Using Anti Tumor Necrosis Factor Antibody (Infliximab) for Treatment of Acute Graft Versus Host Disease |
https://ClinicalTrials.gov/show/NCT00228839 |
Completed |
Emory University |
NA |
| NCT00224874 |
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302) |
https://ClinicalTrials.gov/show/NCT00224874 |
Completed |
National Heart, Lung, and Blood Institute (NHLBI) |
2009-01-31 |
| NCT00201799 |
Infliximab for the Prevention of Graft-versus-Host Disease Following Allogenic Hematopoietic Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT00201799 |
Completed |
Ohio State University Comprehensive Cancer Center |
2006-08-31 |
| NCT00201786 |
Phase II Trial of Pentostatin in Steroid Refractory Acute Graft Versus Host Disease |
https://ClinicalTrials.gov/show/NCT00201786 |
Completed |
Ohio State University Comprehensive Cancer Center |
2007-10-31 |
| NCT00195481 |
Study Evaluating Sirolimus in Kidney Transplant Recipients in India |
https://ClinicalTrials.gov/show/NCT00195481 |
Completed |
Wyeth is now a wholly owned subsidiary of Pfizer |
2005-12-31 |
| NCT00195468 |
Study Comparing Cyclosporine Dose Reduction vs. Cyclosporine Elimination in Kidney Transplant Recipients Taking Sirolimus |
https://ClinicalTrials.gov/show/NCT00195468 |
Completed |
Wyeth is now a wholly owned subsidiary of Pfizer |
2006-11-30 |
| NCT00195429 |
A Study Comparing the Withdrawal of Steroids or Tacrolimus in Kidney Transplant Recipients |
https://ClinicalTrials.gov/show/NCT00195429 |
Completed |
Wyeth is now a wholly owned subsidiary of Pfizer |
NA |
| NCT00195273 |
Study Evaluating Sirolimus in Kidney Transplant Recipients |
https://ClinicalTrials.gov/show/NCT00195273 |
Completed |
Wyeth is now a wholly owned subsidiary of Pfizer |
2008-07-31 |
| NCT00189748 |
A Study to Assess the Safety and Efficacy of a Tacrolimus New Oral Formulation (MR4) in BMT Patients-Extension- |
https://ClinicalTrials.gov/show/NCT00189748 |
Completed |
Astellas Pharma Inc |
NA |
| NCT00189488 |
Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation |
https://ClinicalTrials.gov/show/NCT00189488 |
Completed |
Swedish Orphan Biovitrum |
2008-11-30 |
| NCT00186667 |
Sirolimus as Primary Therapy for the Treatment of Chronic Graft Versus Host Disease |
https://ClinicalTrials.gov/show/NCT00186667 |
Completed |
Stanford University |
2000-01-31 |
| NCT00185692 |
Allogeneic Transplantation From Related Haploidentical Donors |
https://ClinicalTrials.gov/show/NCT00185692 |
Completed |
Stanford University |
2010-12-31 |
| NCT00180089 |
Budesonide for Prevention of Acute Gastrointestinal GVHD Following Allogenic Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT00180089 |
Completed |
Technische Universität Dresden |
2009-03-31 |
| NCT00167947 |
Study Evaluating Sirolimus in Kidney Transplant Recipients. |
https://ClinicalTrials.gov/show/NCT00167947 |
Completed |
Wyeth is now a wholly owned subsidiary of Pfizer |
2007-07-31 |
| NCT00146978 |
Intra-Arterial Catheter Directed Therapy for Severe Graft vs. Host Disease (GVHD) |
https://ClinicalTrials.gov/show/NCT00146978 |
Completed |
Hadassah Medical Organization |
NA |
| NCT00146614 |
Tacrolimus, Sirolimus and Methotrexate as Graft Versus Host Disease Prophylaxis After Blood Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT00146614 |
Completed |
Dana-Farber Cancer Institute |
2003-04-30 |
| NCT00144703 |
Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT00144703 |
Completed |
Dana-Farber Cancer Institute |
2006-11-30 |
| NCT00144677 |
Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT00144677 |
Completed |
Dana-Farber Cancer Institute |
2006-06-30 |
| NCT00144430 |
Pentostatin for High Risk and Refractory Chronic Graft Versus Host Disease in Children |
https://ClinicalTrials.gov/show/NCT00144430 |
Completed |
Ann & Robert H Lurie Children’s Hospital of Chicago |
2008-08-31 |
| NCT00141739 |
Study of Etanercept for the Prevention of Complications Resulting From Hematopoietic Stem Cell Transplantation (HSCT) |
https://ClinicalTrials.gov/show/NCT00141739 |
Completed |
University of Michigan Rogel Cancer Center |
2011-08-31 |
| NCT00141713 |
The Use of Etanercept (Enbrel®) in the Treatment of Acute Graft-Versus-Host Disease |
https://ClinicalTrials.gov/show/NCT00141713 |
Completed |
University of Michigan Rogel Cancer Center |
2006-11-30 |
| NCT00136903 |
Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD) |
https://ClinicalTrials.gov/show/NCT00136903 |
Completed |
Mesoblast, Ltd. |
2006-07-28 |
| NCT00136396 |
Rituximab Therapy for Steroid-Refractory Chronic Graft Versus Host Disease |
https://ClinicalTrials.gov/show/NCT00136396 |
Completed |
Dana-Farber Cancer Institute |
2006-11-30 |
| NCT00130754 |
Thymoglobuline in Non-myeloablative Allogeneic Stem-cell Transplantation |
https://ClinicalTrials.gov/show/NCT00130754 |
Completed |
Hadassah Medical Organization |
NA |
| NCT00128739 |
Treatment of Gastro-Intestinal and/or Hepatic Graft Versus Host Disease With Budesonide in Patients Following Peripheral Blood Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT00128739 |
Completed |
Rafa Laboratories |
NA |
| NCT00102583 |
Cyclosporine Implant for Ocular Graft-Versus-Host Disease |
https://ClinicalTrials.gov/show/NCT00102583 |
Completed |
National Institutes of Health Clinical Center (CC) |
2011-03-15 |
| NCT00096161 |
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00096161 |
Completed |
Fred Hutchinson Cancer Research Center |
2015-02-28 |
| NCT00096096 |
Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT00096096 |
Completed |
Fred Hutchinson Cancer Research Center |
2006-05-31 |
| NCT00089037 |
Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT00089037 |
Completed |
Fred Hutchinson Cancer Research Center |
2005-04-30 |
| NCT00003662 |
Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases |
https://ClinicalTrials.gov/show/NCT00003662 |
Completed |
Roswell Park Cancer Institute |
2001-01-31 |
| NCT00003661 |
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00003661 |
Completed |
Roswell Park Cancer Institute |
1999-11-30 |
| NCT00088543 |
Thymoglobulin to Prevent Acute Graft vs. Host Disease (GvHD) in Patients With Acute Lymphocytic Leukemia (ALL) or Acute Myelogenous Leukemia (AML) Receiving a Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00088543 |
Completed |
Sanofi |
2006-04-30 |
| NCT00002833 |
Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia |
https://ClinicalTrials.gov/show/NCT00002833 |
Completed |
M.D. Anderson Cancer Center |
2002-04-30 |
| NCT00003894 |
Thalidomide in Treating Patients With Chronic Graft-Versus-Host Disease Following Bone Marrow Transplant |
https://ClinicalTrials.gov/show/NCT00003894 |
Completed |
Roswell Park Cancer Institute |
2000-01-31 |
| NCT00005988 |
Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy |
https://ClinicalTrials.gov/show/NCT00005988 |
Completed |
Dana-Farber Cancer Institute |
2001-06-16 |
| NCT00003398 |
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00003398 |
Completed |
University of Maryland, Baltimore |
2000-05-31 |
| NCT00003270 |
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00003270 |
Completed |
Roswell Park Cancer Institute |
2017-10-16 |
| NCT00002456 |
Graft-Versus-Host Disease Prevention in Treating Patients Who Are Undergoing Bone Marrow Transplantation |
https://ClinicalTrials.gov/show/NCT00002456 |
Completed |
Fred Hutchinson Cancer Research Center |
NA |
| NCT00010283 |
Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon |
https://ClinicalTrials.gov/show/NCT00010283 |
Completed |
Fred Hutchinson Cancer Research Center |
2002-07-31 |
| NCT00079183 |
Sirolimus as Secondary Therapy in Chronic Graft-Versus-Host Disease Not Responding To Prior Treatment |
https://ClinicalTrials.gov/show/NCT00079183 |
Completed |
Fred Hutchinson Cancer Research Center |
2009-07-31 |
| NCT00004904 |
Stem Cell Transplantation in Treating Patients With Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00004904 |
Completed |
Northwestern University |
2000-07-31 |
| NCT00074035 |
Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease |
https://ClinicalTrials.gov/show/NCT00074035 |
Completed |
Alliance for Clinical Trials in Oncology |
2008-08-31 |
| NCT00003414 |
Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin’s Disease |
https://ClinicalTrials.gov/show/NCT00003414 |
Completed |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2004-05-31 |
| NCT00004255 |
Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Undergoing Bone Marrow Transplantation |
https://ClinicalTrials.gov/show/NCT00004255 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00004232 |
Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00004232 |
Completed |
Northwestern University |
2002-10-31 |
| NCT00056875 |
Recombinant Human Keratinocyte Growth Factor in Unrelated and Related Transplants |
https://ClinicalTrials.gov/show/NCT00056875 |
Completed |
FDA Office of Orphan Products Development |
NA |
| NCT00055666 |
Compassionate Use of Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Gastrointestinal Tract |
https://ClinicalTrials.gov/show/NCT00055666 |
Completed |
Roswell Park Cancer Institute |
2005-02-28 |
| NCT00054613 |
Safety and Efficacy Study of Photopheresis Plus Standard Therapy to Treat Chronic Graft-versus-Host Disease |
https://ClinicalTrials.gov/show/NCT00054613 |
Completed |
Mallinckrodt |
NA |
| NCT00054600 |
Safety and Efficacy Study of Photopheresis With UVADEX to Prevent Graft-versus-Host Disease |
https://ClinicalTrials.gov/show/NCT00054600 |
Completed |
Mallinckrodt |
NA |
| NCT00054340 |
Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative Disorder |
https://ClinicalTrials.gov/show/NCT00054340 |
Completed |
Fred Hutchinson Cancer Research Center |
NA |
| NCT00053976 |
Methylprednisolone With or Without Daclizumab in Treating Patients With Acute Graft-Versus-Host Disease |
https://ClinicalTrials.gov/show/NCT00053976 |
Completed |
Dana-Farber Cancer Institute |
2003-11-30 |
| NCT00053157 |
Sargramostim in Reducing Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplantation for Hematologic Cancer or Aplastic Anemia |
https://ClinicalTrials.gov/show/NCT00053157 |
Completed |
Roswell Park Cancer Institute |
2004-08-31 |
| NCT00043147 |
Beclomethasone Plus Prednisone in Treating Patients With Graft-Versus-Host Disease |
https://ClinicalTrials.gov/show/NCT00043147 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00031824 |
Hydroxychloroquine in Treating Patients With Newly Diagnosed Chronic Graft-Versus-Host Disease |
https://ClinicalTrials.gov/show/NCT00031824 |
Completed |
Children’s Oncology Group |
2005-05-31 |
| NCT00025662 |
Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS |
https://ClinicalTrials.gov/show/NCT00025662 |
Completed |
National Institutes of Health Clinical Center (CC) |
2008-02-29 |
| NCT00014469 |
Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Advanced Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00014469 |
Completed |
Memorial Sloan Kettering Cancer Center |
2007-05-31 |
| NCT00003538 |
Prevention of Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation |
https://ClinicalTrials.gov/show/NCT00003538 |
Completed |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2004-05-31 |
| NCT00003335 |
Umbilical Cord Blood Transplantation in Treating Patients With High-Risk Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00003335 |
Completed |
Case Comprehensive Cancer Center |
2007-11-30 |
| NCT00001748 |
HLA-Mismatched Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT00001748 |
Completed |
National Institutes of Health Clinical Center (CC) |
NA |
| NCT00048789 |
Extracorporeal Photopheresis to Treat Chronic Graft-Versus-Host Disease |
https://ClinicalTrials.gov/show/NCT00048789 |
Completed |
National Institutes of Health Clinical Center (CC) |
NA |
| NCT00044720 |
Study Evaluating Sirolimus in End Stage Renal Disease in High Risk Kidney Transplant Recipients |
https://ClinicalTrials.gov/show/NCT00044720 |
Completed |
Wyeth is now a wholly owned subsidiary of Pfizer |
2005-07-31 |
| NCT00037531 |
Study Evaluating Sirolimus (Rapamuneâ„¢) in Solid Organ Transplant Recipients |
https://ClinicalTrials.gov/show/NCT00037531 |
Completed |
Wyeth is now a wholly owned subsidiary of Pfizer |
2004-08-31 |
| NCT00035880 |
Study Comparing ABX-CBL (Monoclonal Antibody) Versus Atgam in Patients With Steroid Resistant Acute Graft Versus Host Disease |
https://ClinicalTrials.gov/show/NCT00035880 |
Completed |
Abgenix |
NA |
| NCT00032292 |
Research Study of Visilizumab for Treatment of Acute Graft Versus Host Disease |
https://ClinicalTrials.gov/show/NCT00032292 |
Completed |
Facet Biotech |
2006-08-31 |
| NCT00031148 |
Keratinocyte Growth Factor to Prevent Acute GVHD |
https://ClinicalTrials.gov/show/NCT00031148 |
Completed |
FDA Office of Orphan Products Development |
NA |
| NCT00006747 |
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00006747 |
Completed |
Alliance for Clinical Trials in Oncology |
2003-02-28 |
| NCT00023530 |
Blood and Marrow Transplant Clinical Research Network |
https://ClinicalTrials.gov/show/NCT00023530 |
Completed |
National Heart, Lung, and Blood Institute (NHLBI) |
NA |
| NCT00189761 |
A Study to Assess Efficacy, Safety and Pharmacokinetics of a Tacrolimus New Oral Formulation (MR4) in BMT Recipients |
https://ClinicalTrials.gov/show/NCT00189761 |
Completed |
Astellas Pharma Inc |
NA |
| NCT00109993 |
Campath-1H + FK506 and Methylprednisolone for GVHD |
https://ClinicalTrials.gov/show/NCT00109993 |
Completed |
Case Comprehensive Cancer Center |
2006-06-30 |
| NCT00007059 |
Study of the Pharmacokinetics of Mycophenolate Mofetil in Patients Who Have Undergone Orthotopic Liver Transplantation |
https://ClinicalTrials.gov/show/NCT00007059 |
Completed |
National Center for Research Resources (NCRR) |
NA |
| NCT00001873 |
The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood Cancers |
https://ClinicalTrials.gov/show/NCT00001873 |
Completed |
National Institutes of Health Clinical Center (CC) |
2007-12-28 |
| NCT00001830 |
Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants |
https://ClinicalTrials.gov/show/NCT00001830 |
Completed |
National Institutes of Health Clinical Center (CC) |
NA |
| NCT00001637 |
Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults |
https://ClinicalTrials.gov/show/NCT00001637 |
Completed |
National Institutes of Health Clinical Center (CC) |
2008-07-28 |
| NCT00001623 |
Bone Marrow Transplant Studies for Safe and Effective Treatment of Leukemia |
https://ClinicalTrials.gov/show/NCT00001623 |
Completed |
National Institutes of Health Clinical Center (CC) |
2008-01-31 |
| NCT00001561 |
Active Immunization of Sibling Bone Marrow Transplant Donors Against Purified Myeloma Protein of the Recipient Undergoing Allogeneic Bone Marrow Transplantation |
https://ClinicalTrials.gov/show/NCT00001561 |
Completed |
National Institutes of Health Clinical Center (CC) |
NA |
| NCT00001144 |
Modified Bone Marrow Stem Cell Transplantation for Chronic Myelogenous Leukemia |
https://ClinicalTrials.gov/show/NCT00001144 |
Completed |
National Institutes of Health Clinical Center (CC) |
NA |
| NCT00000591 |
T-Cell Depletion in Unrelated Donor Marrow Transplantation |
https://ClinicalTrials.gov/show/NCT00000591 |
Completed |
National Heart, Lung, and Blood Institute (NHLBI) |
NA |